R Chadarevian
Overview
Explore the profile of R Chadarevian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma
Kerkhofs T, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller H, et al.
J Clin Endocrinol Metab
. 2013 Sep;
98(12):4759-67.
PMID: 24057287
Context: Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully elucidated and different dosing regimens have never been compared head to head....
2.
Jublanc C, Beaudeux J, Aubart F, Raphael M, Chadarevian R, Chapman M, et al.
Nutr Metab Cardiovasc Dis
. 2010 Aug;
21(10):817-22.
PMID: 20685094
Serum levels of ICAM-1 (Inter Cellular Adhesion Molecule-1), VCAM-1 (Vascular cell Adhesion Molecule-1-I), TIMP-1 (tissue inhibitor of metalloproteinases 1) and MMP-9 (Metalloproteinase 9) are well established markers of inflammation. The...
3.
Danchin N, Chadarevian R, Gayet J, Licour M, Valensi P
Ann Cardiol Angeiol (Paris)
. 2007 May;
56(2):82-7.
PMID: 17484092
Many patients at high cardiovascular risk still fail to achieve recommended LDL-C goals. Showing evidence of a difference between two statins at the same dose can significantly contribute to selecting...
4.
Ferrieres J, Durack-Bown I, Giral P, Chadarevian R, Benkritly A, Bruckert E
Ann Cardiol Angeiol (Paris)
. 2006 Feb;
55(1):27-31.
PMID: 16457033
For more than 10 years, preventive cardiology has obtained many positive results. Cardiologists can alter the prognosis of cardiovascular disease in primary and secondary prevention. In primary prevention or during...
5.
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism
Chadarevian R, Jublanc C, Bruckert E, Giral P, Ankri A, Leenhardt L, et al.
J Endocrinol Invest
. 2005 Aug;
28(5):398-404.
PMID: 16075920
Objective: We previously demonstrated that patients suffering from moderate hypothyroidism were at increased risk of thrombosis contrasting with the bleeding tendency of those presenting severe hypothyroidism. The latter state is...
6.
Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, Leguern E, et al.
J Clin Endocrinol Metab
. 2002 Aug;
87(8):3893-901.
PMID: 12161529
Our study aims to provide a comprehensive view of the endocrine features in Kennedy's disease (KD). Twenty-two men with KD underwent detailed endocrine investigations. Clinical signs of partial androgen resistance...
7.
Neuman O, Bruckert E, Chadarevian R, Jacob N, Turpin G
Therapie
. 2002 Mar;
56(6):793-7.
PMID: 11878112
The adrenolytic agent, Op'DDD (Mitotane) has been employed for almost 50 years for treatment of Cushing's syndrome. Despite clinical observations of elevation of hepatic enzymes encountered in patients taking the...
8.
Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G
J Clin Endocrinol Metab
. 2001 Feb;
86(2):732-7.
PMID: 11158038
T(4) levels are determinant of several components of the fibrinolytic system. However, relationships between hypothyroidism and alteration of fibrinolytic capacity are not well established, and published data remain conflicting. As...
9.
Chadarevian R, Bruckert E, Giral P, Turpin G
Blood Coagul Fibrinolysis
. 2000 Jan;
10(8):481-6.
PMID: 10636459
Hypothyroid patients may have several haemostatic abnormalities such as modification of the coagulation proteins and a bleeding tendency. However, conflicting data have been reported, although in some reports, the groups...
10.
Chadarevian R, Bruckert E, Dejager S, Presberg P, Turpin G
Thromb Res
. 1999 Dec;
96(3):175-82.
PMID: 10588459
Increased factor VIIc (FVIIc) and plasminogen activator inhibitor type 1 (PAI-1) levels may lead to a thrombotic state and subsequently to a higher risk of myocardial infarction. The relationships between...